Invesco Ltd. Boosts Holdings in Boston Scientific Corporation $BSX

Invesco Ltd. lifted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 1.4% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 16,851,518 shares of the medical equipment provider's stock after acquiring an additional 226,578 shares during the quarter. Invesco Ltd. owned 1.14% of Boston Scientific worth $1,810,022,000 at the end of the most recent quarter.

• Beware the Death Cross: 3 Stocks Triggering This Spooky Signal

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Riverwater Partners LLC boosted its position in Boston Scientific by 3.3% during the second quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider's stock valued at $333,000 after buying an additional 98 shares during the period. IVC Wealth Advisors LLC increased its holdings in shares of Boston Scientific by 4.9% in the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider's stock worth $236,000 after buying an additional 102 shares during the period. Rise Advisors LLC lifted its stake in shares of Boston Scientific by 13.9% in the 1st quarter. Rise Advisors LLC now owns 844 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 103 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its holdings in Boston Scientific by 3.9% during the 2nd quarter. Sound View Wealth Advisors Group LLC now owns 2,738 shares of the medical equipment provider's stock valued at $294,000 after acquiring an additional 103 shares during the period. Finally, Scotia Capital Inc. grew its position in Boston Scientific by 0.7% during the 2nd quarter. Scotia Capital Inc. now owns 15,093 shares of the medical equipment provider's stock worth $1,621,000 after acquiring an additional 104 shares during the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

NYSE:BSX opened at $99.03 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The firm's fifty day simple moving average is $99.28 and its 200 day simple moving average is $102.19. The stock has a market cap of $146.80 billion, a P/E ratio of 52.96, a price-to-earnings-growth ratio of 2.03 and a beta of 0.67. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50.

• 3 Healthcare Stocks Using AI to Drive Growth

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The company's revenue for the quarter was up 20.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on BSX shares. Weiss Ratings reiterated a "buy (b-)" rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Erste Group Bank downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. BTIG Research reiterated a "buy" rating and set a $132.00 price target on shares of Boston Scientific in a report on Friday, November 21st. Wells Fargo & Company raised their price target on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an "overweight" rating in a report on Thursday, October 23rd. Finally, Robert W. Baird boosted their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an "outperform" rating in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $123.77.

• 3 Biotech Catalysts Present Major Opportunity

Read Our Latest Analysis on Boston Scientific

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company's stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares of the company's stock, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 143,095 shares of company stock worth $14,228,950 over the last three months. Company insiders own 0.50% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Featured Articles

• Five stocks we like better than Boston Scientific
• How to Use the MarketBeat Excel Dividend Calculator
• Wall Street’s Sleeping Giant: Is Amazon About to Wake Up?
• How to Short a Stock in 5 Easy Steps
• Checkmate in the Cloud: ServiceNow's Shopping Spree
• What is Insider Trading? What You Can Learn from Insider Trading
• The Contrarian Case for MSTR Amid MSCI Delisting Debacle

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Boston Scientific Right Now?

Before you consider Boston Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.

While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here